RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.
The conversation is about using bicalutamide, taken less frequently than daily, for hair loss treatment. The user is considering 50mg every 3 days or once a week and is asking for others' experiences.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
A 17-year-old is experiencing hair thinning all over, possibly due to low vitamin D levels. They are advised to consider vitamin D supplementation and check other factors like iron or thyroid function.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The conversation discusses hair thinning and the potential role of vitamin D deficiency in hair loss, with suggestions to take vitamin D3 supplements. The user also mentions having diffuse thinning and a slightly receding hairline.
A woman with hair loss discovered she has thyroid cancer, which was found during an MRI and confirmed with an ultrasound. She advises others with symptoms to see a doctor and shares that her cancer was detected after her dog sniffed her neck and she experienced neck pain.
A user discussed a significant hair recovery using alfatradiol and fluridil but was considered untrustworthy and the post was deleted. They are seeking the original poster's username.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.
The conversation is about personal experiences with Alfatradiol (Pantostin) for hair loss and whether it causes shedding similar to Minoxidil. People are sharing their experiences with this treatment.
The user wants to mix 0.2 ml of RU58841 solution with 2 ml of Alfatradiol to use 10 mg of RU58841 daily due to concerns about side effects. They are asking if this combination would be effective for hair loss treatment.